The above preclinical studies have shown that inhibition of immune checkpoint pairs can attenuate the progression of pulmonary fibrosis, and that inhibition of PD-L1, in particular, can produce an antifibrotic effect. The gene discussed is CD274; the disease is pulmonary fibrosis.